| Literature DB >> 33603441 |
Zhicheng Yang1, Shuaikun Liu2, Li Zhou1, Hui Zhang1, Nanwei Xu1.
Abstract
INTRODUCTION: T-cell immunoglobulin and mucin domain-4 (TIMD-4) are likely to impact autoimmune diseases (e.g., rheumatoid arthritis (RA)). It is hypothesized here that TIMD-4 gene polymorphism is likely to display a correlation with the RA risk.Entities:
Keywords: Chinese population; TIMD-4; polymorphism; rheumatoid arthritis
Year: 2021 PMID: 33603441 PMCID: PMC7881774 DOI: 10.2147/PGPM.S287688
Source DB: PubMed Journal: Pharmgenomics Pers Med ISSN: 1178-7066
Patient Demographics and Risk Factors in Rheumatoid Arthritis
| Variables | Cases (n=379) | Controls (n=432) | |
|---|---|---|---|
| Age, years | 54.65 ± 13.52 | 54.73 ±10.78 | 0.931 |
| Gender, no. (%) | 0.482 | ||
| Male | 91 (24.01) | 113 (26.16) | |
| Female | 288 (75.99) | 319 (73.84) | |
| Smoking, no. (%) | 0.647 | ||
| Yes | 133 (35.09) | 145 (33.56) | |
| No | 246 (64.91) | 287 (66.44) | |
| Alcohol, no. (%) | 0.436 | ||
| Yes | 162 (42.74) | 173 (40.04) | |
| No | 217 (57.26) | 259 (59.95) | |
| ESR, mm/h | 30.41 ± 10.20 | ||
| CRP, mg/l | 15.04 ± 5.16 | ||
| Age at onset, years, mean ± SD | 48.58 ± 10.64 | ||
| Disease duration, years, mean ± SD | 6.07 ± 3.01 | ||
| DAS28 | 4.62 ± 1.03 | ||
| RF positive, no. (%) | |||
| Positive | 309 (81.53) | ||
| Negative | 70 (18.47) | ||
| Anti-ccp positive, no. (%) | |||
| Positive | 321 (84.70) | ||
| Negative | 58 (15.30) | ||
| Functional class, no. (%) | |||
| I | 42 (11.08) | ||
| II | 172 (45.38) | ||
| III | 132 (34.83) | ||
| IV | 33 (8.71) | ||
| Treatment, no. (%) | |||
| MTX | 258 (68.07) | ||
| Biological DMARD | 74 (19.53) | ||
| Others | 47 (12.40) |
Note: Values are statistically significant (P<0.05).
Abbreviations: ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; RF, rheumatoid factor; MTX, methotrexate; DMARD, disease-modifying anti-rheumatic drug.
Logistic Regression Analysis of Associations Between TIMD-4 rs7700944 Polymorphism and Risk of Rheumatoid Arthritis
| Models | Genotype | Case, n(%) | Control, n(%) | OR(95% CI) | *OR(95% CI) | ||
|---|---|---|---|---|---|---|---|
| Co-dominant | GG | 232(61.2) | 299(69.2) | 1.00 | - | 1.00 | - |
| Heterozygote | GA | 129(34.0) | 121(28.0) | ||||
| Homozygote | AA | 18(4.8) | 12(2.8) | 1.93(0.91–4.09) | 0.085 | 1.92(0.91–4.07) | 0.089 |
| Dominant | GG | 232 (61.2) | 299 (69.2) | 1.00 | - | 1.00 | - |
| AA+GA | 147(38.8) | 133(30.8) | |||||
| Recessive | GA+GG | 361(95.2) | 420(97.2) | 1.00 | - | 1.00 | - |
| AA | 18(4.8) | 12(2.8) | 1.75(0.83–3.67) | 0.142 | 1.73(0.81–3.64) | 0.150 | |
| Allele | G | 593(78.2) | 719(83.2) | 1.00 | - | - | - |
| A | 165(21.8) | 145(16.8) | - | - |
Notes: *Adjust age, gender, smoking, and alcohol. Bold values are statistically significant (P <0.05).
Stratified Analyses Between the TIMD-4 rs7700944 Polymorphism and the Risk of Rheumatoid Arthritis
| Variables | (Case/Control) | GA vs GG | AA vs GG | AA vs GG+GA | AA+GA vs GG | ||
|---|---|---|---|---|---|---|---|
| GG | GA | AA | OR(95% CI); | OR(95% CI); | OR(95% CI); | OR(95% CI); | |
| Sex | |||||||
| Male | 59/67 | 26/39 | 6/7 | 0.76(0.41–1.39); 0.369 | 0.97(0.31–3.06); 0.963 | 1.07(0.35–3.30); 0.908 | 0.79(0.45–1.40); 0.418 |
| Female | 173/232 | 103/82 | 12/5 | 2.73(0.95–7.85); 0.053 | |||
| Smoking | |||||||
| Yes | 66/93 | 60/47 | 7/5 | 1.97(0.60–6.49); 0.256 | 1.56(0.48–5.03); 0.457 | ||
| No | 166/206 | 69/74 | 11/7 | 1.16(0.79–1.70); 0.459 | 1.95(0.74–5.14); 0.170 | 1.87(0.71–4.91); 0.195 | 1.23(0.85–1.78); 0.281 |
| Alcohol | |||||||
| Yes | 102/126 | 51/41 | 9/6 | 1.54(0.94–2.50); 0.083 | 1.85(0.64–5.38); 0.250 | 1.64(0.57–4.71); 0.356 | 1.58(0.99–2.50); 0.053 |
| No | 130/173 | 78/80 | 9/6 | 1.30(0.88–1.91); 0.186 | 2.00(0.69–5.75); 0.193 | 1.82(0.64–5.21); 0.255 | 1.35(0.93–1.96); 0.120 |
| Age (years) | |||||||
| <55 | 122/153 | 61/66 | 8/6 | 1.16(0.76–1.77); 0.492 | 1.67(0.57–4.95); 0.348 | 1.60(0.54–4.68); 0.391 | 1.20(0.80–1.81); 0.376 |
| ≥55 | 110/146 | 68/55 | 10/6 | 2.21(0.78–6.27); 0.127 | 1.88(0.67–5.28); 0.223 | ||
Note: Bold values are statistically significant (P <0.05).
The Associations Between the TIMD-4 rs7700944 Polymorphism and Clinical Characteristics of Rheumatoid Arthritis
| Characteristics | Genotype Distributions | |||
|---|---|---|---|---|
| GG | GA | AA | GA+AA | |
| DAS28 | ||||
| ≥3.20/<3.20 | 174/58 | 112/17 | 12/6 | 124/23 |
| OR (95% CI); | 1.0 (reference) | 0.67(0.24–1.86); 0.617 | ||
| CRP (mg/l) | ||||
| ≥10.00/<10.00 | 183/49 | 96/33 | 13/5 | 109/38 |
| OR (95% CI); | 1.0 (reference) | 0.78(0.47–1.29); 0.332 | 0.70(0.24–2.05); 0.509 | 0.77(0.47–1.25); 0.286 |
| ESR (mm/h) | ||||
| ≥25.00/<25.00 | 155/77 | 102/27 | 10/8 | 112/35 |
| OR (95% CI); | 1.0 (reference) | 0.62(0.24–1.64); 0.332 | 1.59(0.99–2.54); 0.051 | |
| RF status | ||||
| Positive/Negative | 191/41 | 106/23 | 12/6 | 118/29 |
| OR (95% CI); | 1.0 (reference) | 0.99(0.56–1.74); 0.970 | 0.43(0.15–1.21); 0.185 | 0.87(0.52–1.48); 0.615 |
| Anti-ccp status | ||||
| Positive/Negative | 189/43 | 116/13 | 16/2 | 132/15 |
| OR (95% CI); | 1.0 (reference) | 1.82(0.40–8.21); 0.637 | ||
| Functional class | ||||
| III+IV/I+II | 107/125 | 53/76 | 5/13 | 58/89 |
| OR (95% CI); | 1.0 (reference) | 0.82(0.53–1.26); 0.356 | 0.45(0.16–1.30); 0.132 | 0.76(0.50–1.16); 0.202 |
| Treatment | ||||
| MTX/non-MTX | 156/76 | 91/38 | 11/7 | 102/45 |
| OR (95% CI); | 1.0 (reference) | 1.17(0.73–1.86); 0.518 | 0.77(0.29–2.05); 0.595 | 1.10(0.71–1.72);0.662 |
Note: Bold values are statistically significant (P <0.05).
Figure 1Associations among the serum level of TIMD-4 and genotype frequency in RA patients and healthy controls (**P < 0.01).